Comparative efficacy of rituximab in biologic/targeted synthetic DMARD-naive versus exposed rheumatoid arthritis patients: a retrospective cohort study

Sertaç Ketenci; Mete Kara

Makale detayları

Comparative efficacy of rituximab in biologic/targeted synthetic DMARD-naive versus exposed rheumatoid arthritis patients: a retrospective cohort study

Yazarlar:

Sertaç Ketenci | Mete Kara

Yayıncı:

Hatay Mustafa Kemal University

Ana Başlıklar:

Internal Diseases

Dergi:

Interdisciplinary Medical Journal Vol.16 Issue 55, pp.84-91

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001356115

pISSN:

2980-1915

Anahtar kelimeler:

Özet:

 Objective: To compare the efficacy and safety of rituximab in patients with rheumatoid arthritis RA who were either biologictargeted synthetic DMARD bDMARDtsDMARD-naive or previously exposed. Methods: In this retrospective cohort study, 120 RA patients treated with rituximab between June 2020 and December 2023 were included. Patients were categorized as bDMARDtsDMARD-naive n66 or -exposed n54. Clinical efficacy was assessed by change in Disease Activitity Score 28 DAS28-CRP and the proportion achieving low disease activity LDA; DAS28-CRP 3.2 after treatment. Safety outcomes included infusion-related reactions IRRs, infections, and hypogammaglobulinemia. Results: The naive group showed significantly greater improvement in disease activity ΔDAS28-CRP: 2.5 vs. 1.9, p0.001 and higher LDA achievement 62.1 vs. 46.2, p0.030 compared to the exposed group. Rates of IRRs 16.6 vs. 18.5, p0.820, infections 1.5 vs. 1.9, p0.880, and hypogammaglobulinemia were comparable between groups. Most IRRs were mild grade 12; only one serious IRR occurred, with no cases requiring prolonged hospitalization. One patient in the exposed group experienced hepatitis B reactivation, managed effectively with antiviral therapy. Primary and secondary inefficacy were the most common reasons for rituximab discontinuation, with no significant differences between groups. Conclusion: Rituximab demonstrated superior efficacy in bDMARDtsDMARD-naive RA patients, while maintaining a comparable safety profile to that in previously exposed patients. These findings support the potential benefit of using Rituximab earlier in the treatment sequence for selected RA patients.

 Objective: To compare the efficacy and safety of rituximab in patients with rheumatoid arthritis RA who were either biologictargeted synthetic DMARD bDMARDtsDMARD-naive or previously exposed. Methods: In this retrospective cohort study, 120 RA patients treated with rituximab between June 2020 and December 2023 were included. Patients were categorized as bDMARDtsDMARD-naive n66 or -exposed n54. Clinical efficacy was assessed by change in Disease Activitity Score 28 DAS28-CRP and the proportion achieving low disease activity LDA; DAS28-CRP 3.2 after treatment. Safety outcomes included infusion-related reactions IRRs, infections, and hypogammaglobulinemia. Results: The naive group showed significantly greater improvement in disease activity ΔDAS28-CRP: 2.5 vs. 1.9, p0.001 and higher LDA achievement 62.1 vs. 46.2, p0.030 compared to the exposed group. Rates of IRRs 16.6 vs. 18.5, p0.820, infections 1.5 vs. 1.9, p0.880, and hypogammaglobulinemia were comparable between groups. Most IRRs were mild grade 12; only one serious IRR occurred, with no cases requiring prolonged hospitalization. One patient in the exposed group experienced hepatitis B reactivation, managed effectively with antiviral therapy. Primary and secondary inefficacy were the most common reasons for rituximab discontinuation, with no significant differences between groups. Conclusion: Rituximab demonstrated superior efficacy in bDMARDtsDMARD-naive RA patients, while maintaining a comparable safety profile to that in previously exposed patients. These findings support the potential benefit of using Rituximab earlier in the treatment sequence for selected RA patients.

 Objective: To compare the efficacy and safety of rituximab in patients with rheumatoid arthritis RA who were either biologictargeted synthetic DMARD bDMARDtsDMARD-naive or previously exposed. Methods: In this retrospective cohort study, 120 RA patients treated with rituximab between June 2020 and December 2023 were included. Patients were categorized as bDMARDtsDMARD-naive n66 or -exposed n54. Clinical efficacy was assessed by change in Disease Activitity Score 28 DAS28-CRP and the proportion achieving low disease activity LDA; DAS28-CRP 3.2 after treatment. Safety outcomes included infusion-related reactions IRRs, infections, and hypogammaglobulinemia. Results: The naive group showed significantly greater improvement in disease activity ΔDAS28-CRP: 2.5 vs. 1.9, p0.001 and higher LDA achievement 62.1 vs. 46.2, p0.030 compared to the exposed group. Rates of IRRs 16.6 vs. 18.5, p0.820, infections 1.5 vs. 1.9, p0.880, and hypogammaglobulinemia were comparable between groups. Most IRRs were mild grade 12; only one serious IRR occurred, with no cases requiring prolonged hospitalization. One patient in the exposed group experienced hepatitis B reactivation, managed effectively with antiviral therapy. Primary and secondary inefficacy were the most common reasons for rituximab discontinuation, with no significant differences between groups. Conclusion: Rituximab demonstrated superior efficacy in bDMARDtsDMARD-naive RA patients, while maintaining a comparable safety profile to that in previously exposed patients. These findings support the potential benefit of using Rituximab earlier in the treatment sequence for selected RA patients.

 Objective: To compare the efficacy and safety of rituximab in patients with rheumatoid arthritis RA who were either biologictargeted synthetic DMARD bDMARDtsDMARD-naive or previously exposed. Methods: In this retrospective cohort study, 120 RA patients treated with rituximab between June 2020 and December 2023 were included. Patients were categorized as bDMARDtsDMARD-naive n66 or -exposed n54. Clinical efficacy was assessed by change in Disease Activitity Score 28 DAS28-CRP and the proportion achieving low disease activity LDA; DAS28-CRP 3.2 after treatment. Safety outcomes included infusion-related reactions IRRs, infections, and hypogammaglobulinemia. Results: The naive group showed significantly greater improvement in disease activity ΔDAS28-CRP: 2.5 vs. 1.9, p0.001 and higher LDA achievement 62.1 vs. 46.2, p0.030 compared to the exposed group. Rates of IRRs 16.6 vs. 18.5, p0.820, infections 1.5 vs. 1.9, p0.880, and hypogammaglobulinemia were comparable between groups. Most IRRs were mild grade 12; only one serious IRR occurred, with no cases requiring prolonged hospitalization. One patient in the exposed group experienced hepatitis B reactivation, managed effectively with antiviral therapy. Primary and secondary inefficacy were the most common reasons for rituximab discontinuation, with no significant differences between groups. Conclusion: Rituximab demonstrated superior efficacy in bDMARDtsDMARD-naive RA patients, while maintaining a comparable safety profile to that in previously exposed patients. These findings support the potential benefit of using Rituximab earlier in the treatment sequence for selected RA patients.

Makale detayları

Comparative efficacy of rituximab in biologic/targeted synthetic DMARD-naive versus exposed rheumatoid arthritis patients: a retrospective cohort study

Yazarlar:

Sertaç Ketenci | Mete Kara

Yayıncı:

Hatay Mustafa Kemal University

Ana Başlıklar:

Internal Diseases

Dergi:

Interdisciplinary Medical Journal Vol.16 Issue 55, pp.84-91

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001356115

pISSN:

2980-1915

Rituximab

rheumatoid arthritis

biologic drug

treatment outcome

infusion-related reactions

Sayı

Makale detayları

Comparative efficacy of rituximab in biologic/targeted synthetic DMARD-naive versus exposed rheumatoid arthritis patients: a retrospective cohort study

Yazarlar: Sertaç Ketenci | Mete Kara

Yayıncı: Hatay Mustafa Kemal University

Ana Başlıklar: Internal Diseases

Dergi: Interdisciplinary Medical Journal Vol.16 Issue 55, pp.84-91

Belge Tipi: Makale

Yayın Tarihi: 8/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001356115

pISSN: 2980-1915

Rituximab

rheumatoid arthritis

biologic drug

treatment outcome

infusion-related reactions

Sayı

Yazarlar:

Sertaç Ketenci | Mete Kara

Yayıncı:

Hatay Mustafa Kemal University

Ana Başlıklar:

Internal Diseases

Dergi:

Interdisciplinary Medical Journal Vol.16 Issue 55, pp.84-91

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001356115

pISSN:

2980-1915